NaturoMed Therapeutics, the parent company of Stay Wyld Organics, is a vertically integrated functional and medicinal mushroom company. NaturoMed Therapeutics is currently producing bulk functional mushroom powders at its state of the art facility in BC, Canada and selling functional mushroom products to the retail market throughout North America. The company is committed to improving global mental and physical health through the production and distribution of high-quality Canadian grown organic mushroom products. NaturoMed is excited to announce that construction is well underway for its Health Canada Controlled Substances Dealer’s License to produce Psilocybin. Estimated completion is Q4, 2022. NaturoMed plans to produce Psilocybin once it receives the license. NaturoMed’s lead scientist is currently working on new extraction processes to create medicinal IP.
Similar Posts
How to Enroll in a Psychedelic Clinical Trial in 5 Easy Steps
Interested in participating in a psychedelic study? Here’s an in-depth walk through guide so you can take actionable steps to make it happen.
Atai Life Sciences Valued At More Than $3 Billion After IPO
German psychedelic pharmaceutical company Atai Life Sciences is valued at more than $3 billion after its IPO listing on the Nasdaq.
Psilocybin as an Agent for Human and Cultural Development with Jahan Khamsehzadeh Ph.D.
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.
Psychedelic Biotech Company Atai Life Sciences Valued At $2 Billion
Biotech company Atai Life Sciences has earned a $2 billion valuation for its work in developing psychedelic treatments for mental health issues.
MindMed vs. atai Life Sciences (Everything You Need to Know Before Buying MNMD / MMED/ ATAI)
THE MINDMED VS. ATAI discussion you need to hear!
Prior to atai’s IPO on the NASDAQ stock exchange, we repeatedly said that when atai Life Sciences goes public, the company will become MindMed ‘s ( MNMD: NASDAQ) (MMED: NEO) top competitor.
Well, atai did IPO on June 18 under ticker symbol “atai”. For this reason, I invited Jason Najum from Microdose.buzz to have a conversation. In this episode, we have a general discussion about:
– MindMed’s flagship programs and the different businesses and programs ran under atai’s umbrella.
– The companies’ financial capability to run clinical trials.
-MindMed’s and atai’s potential to disrupt the way we treat mental illness within the next 5 to 10 years.
– Potential return on investment for retail investors.
Time Stamps:
0:00 – Intro
4:11 – What is atai’s mission?
6:24 – What is MindMed’s Mission
8:29 – atai’s clinical trial pipeline
19:45 – MindMed’s clinical trial pipeline
24:25 – How do MindMed and atai differ in business structure?
30:40 – Comparing the financials
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Enjoy the episode!
Check out Jason’s writing at:
https://microdose.buzz/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Website: https://thepsychedelicinvestor.com/
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #Atai
Psychedelic Business Spotlight: November 19
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.